Martin Mackay
Senior Vice President & President, PharmaTherapeutics Research & Development

Martin Mackay is the President of Pfizer PharmaTherapeutics Research & Development. Martin oversees an international network of scientists and other pharmaceutical R&D professionals in Research, Development Operations, Pharmaceutical Sciences, Drug Safety, and their functional lines. The PharmaTherapeutics organization is advancing a portfolio of investigational medicines in the following Research Units, Allergy & Respiratory, Antibacterials, Antivirals, Cardiovascular & Metabolic Diseases, Genitourinary, Neuroscience, Oncology , and Pain and in the Indications Discovery and Regenerative Medicine Biotechnology Units.

Martin began his career at Pfizer in 1995 as the Director of Discovery Biology in the UK. In 1997 he became the Senior Director, Head of Biology and in 1998, Vice President, UK Discovery. He was promoted to Senior Vice President, Head of Worldwide Discovery in 1999 and moved to the United States. In 2003, he was appointed as the Senior Vice President, Head of Worldwide Research and Technology. Early in 2007, he was named Vice President PGRD, Head of Worldwide Development. He was appointed President of Pfizer Global Research and Development in September of 2007.

Prior to joining Pfizer, Martin earned a Microbiology First Class Honors Degree at Heriot-Watt University and a PhD in Molecular Genetics at the University of Edinburgh in 1983. Between degrees he worked in Antibacterial Discovery at Beecham Pharmaceuticals in Surrey, UK. Martin conducted his postdoctoral research fellowship working on malarial vaccines with Professor John Scaife at the University of Edinburgh and Professor Uli Certa at Hoffman La-Roche Pharmaceuticals in Basel, Switzerland. Martin joined the Advanced Drug Delivery Research Unit at Ciba-sGeigy in Sussex, UK and became the Head of Drug Preformulation and Delivery at that site. In 1993, he moved to Ciba's headquarters in Basel, Switzerland as Head of Molecular and Cell Biology, CNS Research, where he led an international team of researchers until his move to Pfizer in 1995.